Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics, Inc. (GRCE)
:GRCE
Total Valuation
Grace Therapeutics has a market cap or net worth of $52.61M. The enterprise value is $30.59M.
Market Cap$52.61M
Enterprise Value$30.59M
Share Statistics
Grace Therapeutics has 15,474,026 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,474,026
Owned by Insiders8.48%
Owned by Institutions17.33%
Financial Efficiency
Grace Therapeutics’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -17.84%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-17.84%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee0.00
Profits Per Employee-2.39M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Grace Therapeutics is ―. Grace Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio0.41
Price to Fair Value0.41
Price to FCF-1.85
Price to Operating Cash Flow-4.44
PEG Ratio0.05
Income Statement
In the last 12 months, Grace Therapeutics had revenue of 0.00 and earned -9.57M in profits. Earnings per share was -0.79.
Revenue0.00
Gross Profit0.00
Operating Income-16.68M
Pretax Income-12.77M
Net Income-9.57M
EBITDA-16.67M
Earnings Per Share (EPS)-0.79
Cash Flow
In the last 12 months, operating cash flow was -12.02M and capital expenditures 0.00, giving a free cash flow of -12.02M billion.
Operating Cash Flow-12.02M
Free Cash Flow-12.02M
Free Cash Flow per Share-0.78
Dividends & Yields
Grace Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-10.99%
50-Day Moving Average3.16
200-Day Moving Average2.93
Relative Strength Index (RSI)60.51
Average Volume (3m)57.94K
Important Dates
Grace Therapeutics upcoming earnings date is Feb 16, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateFeb 16, 2026
Ex-Dividend Date―
Financial Position
Grace Therapeutics as a current ratio of 11.77, with Debt / Equity ratio of 0.00%
Current Ratio11.77
Quick Ratio11.77
Debt to Market Cap0.00
Net Debt to EBITDA1.33
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Grace Therapeutics has paid -3.20M in taxes.
Income Tax-3.20M
Effective Tax Rate0.25
Enterprise Valuation
Grace Therapeutics EV to EBITDA ratio is -0.33, with an EV/FCF ratio of -0.36.
EV to Sales0.00
EV to EBITDA-0.33
EV to Free Cash Flow-0.36
EV to Operating Cash Flow-0.36
Balance Sheet
Grace Therapeutics has $16.86M in cash and marketable securities with $0.00 in debt, giving a net cash position of $16.86M billion.
Cash & Marketable Securities$16.86M
Total Debt$0.00
Net Cash$16.86M
Net Cash Per Share$1.09
Tangible Book Value Per Share$1.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Grace Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast45.97%